nifedipine has been researched along with avapro in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Sun, Y; Yan, Z | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Sen, S; Sinha, N | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Angelini, A; Battista Ambrosio, G; Dalla Libera, L; Ravara, B; Rossini, K; Sandri, M; Thiene, G; Vescovo, G | 1 |
| Belloni, AS; Cavallin, M; Mazzocchi, G; Nussdorfer, GG; Pessina, AC; Rossi, GP; Sartore, S | 1 |
| Jiang, YY; Shen, FM; Su, DF; Xie, HH; Zhang, XF | 1 |
| Jiang, Y; Peng, C; Tao, X; Wang, LP; Xie, HH; Yang, H; Zhang, C | 1 |
| Fan, X; Li, J; Wang, Q | 1 |
| Attakora, J; Donkoh, IE; Ephraim, RKD; Essuman, G; Okyere, I; Okyere, P; Serwaa, D | 1 |
1 review(s) available for nifedipine and avapro
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
15 other study(ies) available for nifedipine and avapro
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metabolic Clearance Rate; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship; Sensitivity and Specificity; Software | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Beneficial effects on skeletal muscle of the angiotensin II type 1 receptor blocker irbesartan in experimental heart failure.
Topics: Angiotensin II; Animals; Apoptosis; Biphenyl Compounds; Calcium Channel Blockers; Drug Evaluation, Preclinical; Gene Expression Regulation; Heart Failure; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Infusion Pumps, Implantable; Irbesartan; Male; Monocrotaline; Muscle Fibers, Fast-Twitch; Muscle Fibers, Slow-Twitch; Muscle Proteins; Muscle, Skeletal; Muscular Atrophy; Nifedipine; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Tetrazoles; Tumor Necrosis Factor-alpha | 2001 |
Aortic smooth muscle cell phenotypic modulation and fibrillar collagen deposition in angiotensin II-dependent hypertension.
Topics: Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Genetically Modified; Antihypertensive Agents; Aorta; Biphenyl Compounds; Bosentan; Calcium Channel Blockers; Collagen; Dansyl Compounds; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Hypertension; Immunohistochemistry; Irbesartan; Male; Muscle, Smooth, Vascular; Nifedipine; Rats; Rats, Sprague-Dawley; Sulfonamides; Tetrazoles | 2002 |
Blood pressure variability, baroreflex sensitivity and organ damage in spontaneously hypertensive rats treated with various antihypertensive drugs.
Topics: Animals; Antihypertensive Agents; Aorta; Atenolol; Baroreflex; Biphenyl Compounds; Blood Pressure; Circadian Rhythm; Hydrochlorothiazide; Hypertension; Hypertrophy, Left Ventricular; Irbesartan; Kidney Diseases; Male; Nifedipine; Rats; Rats, Inbred SHR; Tetrazoles | 2006 |
Combination Therapy of Nifedipine and Sulphonylureas Exhibits a Mutual Antagonistic Effect on the Endothelial Cell Dysfunction Induced by Hyperglycemia Linked to Vascular Disease.
Topics: Antihypertensive Agents; Biphenyl Compounds; Cell Movement; Diabetic Angiopathies; Drug Synergism; Endothelial Cells; Glucose; Glyburide; Human Umbilical Vein Endothelial Cells; Humans; Hyperglycemia; Hypoglycemic Agents; Irbesartan; Metformin; Nifedipine; Oxygen; Sulfonylurea Compounds; Tetrazoles | 2016 |
Hypertensive crisis with 2 target organ impairment induced by glycyrrhizin: A case report.
Topics: Anti-Inflammatory Agents; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Cholangitis; Female; Glycyrrhizic Acid; Humans; Hyperaldosteronism; Hypertension, Malignant; Hypertensive Retinopathy; Irbesartan; Kidney Diseases; Middle Aged; Nifedipine; Nitroprusside; Tetrazoles; Treatment Outcome; Withholding Treatment | 2018 |
Conservative therapy is associated with worse clinical features and biochemical derangements than renal replacement therapy: a retrospective study in Kumasi, Ghana.
Topics: Adult; Aspirin; Bisoprolol; Conservative Treatment; Furosemide; Ghana; Humans; Irbesartan; Kidney Failure, Chronic; Lisinopril; Metformin; Middle Aged; Nifedipine; Ranitidine; Renal Replacement Therapy; Retrospective Studies; Sodium | 2022 |